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Abstract 
Common cold sufferers frequently report sleep disruption during the symp-
tomatic period of infections. We examined the effects of treatment with a 
topical aromatic pharmaceutical ointment (Vicks VapoRub®), on associated 
sleep disturbances. The effects of Vicks VapoRub® versus placebo (petrolatum 
ointment) on subjective and objective measured sleep parameters were as-
sessed in an exploratory study of 100 common cold patients, in a randomized, 
single blind, controlled, two-arm, parallel design study. The primary efficacy 
variable was subjective sleep quality measured with the SQSQ (Subjective 
Quality of Sleep Questionnaire). Additional measures included, ease of falling 
asleep and depth of sleep (measured with a post-sleep Visual Analog Scale), 
total sleep time, sleep onset latency, activity score, percentage of sleep, sleep 
efficiency (measured with actigraphy and SQSQ) and sleep quality index 
measured with a modified Karolinska Sleep Diary (KSD). The primary end-
point, “How was the quality of your sleep last night?” showed a statistically 
significant difference in change from baseline in favour of VapoRub treatment 
(p = 0.0392) versus placebo. Positive effects of VapoRub versus placebo were 
also observed for “How refreshed did you feel upon waking up?” (p = 0.0122) 
(SQSQ), “Did you get enough sleep?” (p = 0.0036) (KSD), “How was it to get 
up?” (p = 0.0120) (KSD) and “Do you feel well-rested?” (p = 0.0125) (KSD). 
No statistically significant changes from baseline versus placebo were detected 
in the Actiwatch endpoints. Vicks VapoRub® when applied before retiring to 
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bed can reduce subjective sleep disturbances during a common cold. The re-
sults of this exploratory study support the belief among patients that the use 
of VapoRub improves subjective sleep quality during common cold which was 
associated with more refreshing sleep. 
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Upper Respiratory Tract Infection, Common Cold, VapoRub,  
Sleep Disturbance, Aromatic Oils 
 
1. Introduction 
The common cold, an infection of the upper respiratory tract, is reported to be 
the most common human infectious disease [1] [2]. Adults can experience two 
to four episodes a year and children six to eight [2].  
Common cold is generally a mild illness of the upper respiratory tract, primarily 
affecting the nose, nasopharynx and paranasal sinuses and is readily self-diagnosed 
by sufferers [3]. Rhinoviruses are the most common causative agents accounting 
for up to 50% of symptomatic infections [1]. The main symptoms of common cold 
include nasal congestion, nasal discharge, sneezing, headache, sore throat, and 
cough [4]. Of these, nasal congestion and cough have been reported as the most 
bothersome symptoms of a cold on 6 of the first 7 days of a cold [5]. 
Additionally, it is well recognised that during symptomatic common cold, 
sleep can be adversely affected [6]. While this effect may be considered modest 
(c. 23 minutes decrease in sleep and a 5% reduction in sleep efficiency) from a 
scientific perspective [7], it is generally accepted that common cold-induced 
sleep disruption is clinically meaningful. Smith (2012) [6] showed correlations 
between symptom scores and sleep parameters. In general sleep measures and 
total symptom score were correlated, indicating that increasing symptom sever-
ity was associated with sleep disturbance. The data suggested that nasal conges-
tion severity was a significant driver of the correlation. Therefore, remedies that 
can alleviate rhinitis induced disturbances of sleep without the use of sedation, 
to ensure a well-rested feeling upon awakening, have an important place in 
therapy. 
In the UK and many other countries, Vicks VapoRub® (VVR) is indicated for 
the reduction in cough frequency [8] and feeling of relief from nasal congestion 
[9]. As cough and nasal congestion (regardless of aetiology) are recognised bar-
riers to restful and restorative sleep [10], [11], [12], their relief using a topical 
ointment like VVR can be predicted to improve elements of sleep quality. 
VVR is a pharmaceutical preparation containing a combination of levomen-
thol (2.75% w/w), eucalyptus oil (1.5% w/w), turpentine oil (5% w/w) and cam-
phor (5% w/w) as active ingredients, and thymol, cedarwood oil, and white soft 
paraffin (petrolatum) as excipients. VVR is an ointment that is either applied 
topically to the chest, throat, and back or added to hot water and the aromatic 
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vapours inhaled. When applied to the skin, the active ingredients are evaporated 
by body temperature and inspired into the airways. The therapeutic effects, re-
duction in cough frequency and relief from nasal congestion, are likely due, at 
least in part, to interactions of the aromatics with the largely calcium-selective 
ion channel, transient receptor potential (TRP) receptors. Recent data suggest 
that the transient receptor potential receptors TRPM8, TRPV1 and TRPA1 are 
up-regulated in respiratory virus infected cells [13] [14]. TRPM8 mediates the 
feeling of coolness associated with menthol and eucalyptus oil [15], [16] and so 
is likely the main mediator of the sensation of cooling and nasal decongestion 
associated with menthol and eucalyptus oil [9]. Camphor, eucalyptus oil and 
menthol have been shown to interact with the TRPV1 and TRPA1 receptors [17] 
[18] [19] which are implicated in the neurophysiology of cough [13] [14]. These 
interactions may therefore have a role in controlling cough sensitivity. 
This study compared the effects of VVR versus placebo on subjectively and 
objectively assessed sleep parameters in adult common cold sufferers. Sleep pa-
rameters were measured using subjective questionnaires (Subjective Quality of 
Sleep Questionnaire [SQSQ] [20], a modified Karolinska Sleep Diary [KSD] [21], 
and a study-specific post-sleep questionnaire) and actigraphy, an objective 
method of monitoring rest-activity patterns [22]. Several subjective question-
naires were employed because this was the first exploration of the effect of VVR 
on sleep parameters so little knowledge existed of likely effect size or which ele-
ments of sleep may be affected. Actigraphy was employed as it is a validated ob-
jective albeit surrogate measure of sleep. 
2. Methods 
2.1. Participants 
One hundred and forty-one adult participants were screened for this study and 
100 were enrolled and randomized to the 2 treatment groups (Figure 1). The 
mean (SD) age of those enrolled was 23 years (8.7) with a mean Body Mass In-
dex (BMI) of 23 (2.9). The population was 61% female and most participants 
(71%) were Caucasian. One participant withdrew consent during the study and 
their data were not included. Subjects were recruited by advertisement from the 
staff and students of the University of Surrey and the greater London area. Those 
participating received £120 compensation. 
Randomized participants were suffering from a common cold and experienc-
ing nasal congestion, cough and disturbance to normal sleep. Key inclusion cri-
teria included suffering from a self-diagnosed common cold of no more than 36 
hours duration; suffering from at least mild cough and nasal congestion due to 
the common cold (scores of at least 1 on the 4-point ordinal scale); having an 
average score of < 50 on the 2 responses to the question “How would you com-
pare the quality of last night’s sleep with your usual sleep without a cold?” from 
the Leeds Sleep Evaluation Questionnaire (LSEQ) [23], a 100-mm Visual Analog 
Scale (VAS), where Response 1 is 0 = “Less restful than usual” and 100 = “More  
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Figure 1. Subject disposition. 
 
restful than usual” and Response 2 is 0 = “More periods of wakefulness than 
usual” and 100 = “Fewer periods of wakefulness than usual”. 
Volunteers were excluded if they had any of the following: A previously diag-
nosed sleep disorder, a current sleep disturbance or poor sleep quality unrelated 
to their cold based on the Pittsburgh Sleep Quality Index (PSQI) [24] (i.e., a 
score of >5); a clinically significant nasal abnormality; a history of clinically re-
levant anosmia; were employed on night or rotating shift work or needed to tra-
vel across more than 2 time zones in the 14 days prior to screening or planned to 
do so during the study; a history of allergy or hypersensitivity to any of the in-
gredients of VVR; a history of significant airway disease or pronounced hyper-
sensitivity of the airways/asthma or Chronic Obstructive Pulmonary Disease, a 
significant history of recurrent sinusitis or currently experiencing allergic rhini-
tis, or significant history of chronic cough; a body temperature > 100.5°F 
(38.1˚C); had used, within 5 half-lives, substances or medications known to af-
fect sleep; had used nasal decongestants in the past 24 hours; had a self-reported 
consumption of >5 caffeinated beverages daily; used nicotine in any form; took 
naps daily; used inhaled, topical, or oral nedocromil or cromolyn sodium, tricyc-
lic antidepressant medications, or monoamine oxidase inhibitors for 14 days 
prior to screening; had a history of alcohol or drug abuse within the past 2 years; 
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were currently enrolled in another clinical trial, or had received any other inves-
tigational drug within the past 30 days; if female and of child-bearing potential 
had a positive urine pregnancy test at screening or were lactating; had a history 
of malignancy within the past 2 years, or had current or past history of serious, 
severe, or unstable physical or psychiatric illness; or were taking medication that 
the Investigator believed would interfere with the evaluation of the study, pose a 
safety risk, or confound the interpretation of the study results. 
2.2. Study Design 
The study (EudraCT# 2013-004524-11) was a randomized, single-(Investigator) 
blind, controlled, 2-arm (Vicks VapoRub® [VVR] vs. petrolatum), parallel de-
sign, single site study conducted at Surrey Clinical Research Centre, University 
of Surrey, between November 2014 and May 2015.  
The study was conducted in accordance with the ICH Guideline for Good 
Clinical Practice, 1997; the US CFR Title 21 parts 50, 56 and 312; applicable na-
tional laws and regulations; the ethical requirements of Directive 2001/20/EC; 
and the ethical principles with their origin in the Declaration of Helsinki. The 
study was approved by the NRES Committee London-Brent Ethics Committee 
and all participants provided written informed consent prior to any study pro-
cedures being conducted.  
The study included a baseline visit (Day 0) at the study site to confirm study 
eligibility and to randomly assign subjects to 1 of 2 test products (VVR or petro-
latum). Randomized subjects were sent home with the SQSQ, KSD, and post- 
sleep questionnaire, along with the Actiwatch sleep monitoring equipment and 
their assigned test product. Subjects were instructed to use the Actiwatch on this 
first evening of Day 0, but did not apply test product. Upon waking the next 
morning, subjects completed the SQSQ, KSD, and the post-sleep questionnaire.  
The test period began on the evening of Day 1 when subjects applied their 
randomly assigned test product as directed, immediately before going to bed. 
Subjects continued using the Actiwatch overnight. Upon waking the next 
morning, subjects completed the SQSQ, KSD, and post-sleep questionnaire. 
These procedures were repeated on the evening of Day 2 and the following 
morning. Subjects then returned to the study site on Day 3 to complete exit pro-
cedures and to return their sleep monitoring equipment, completed question-
naires, and test product containers with any remaining study test product. At 
this point, the subjects exited from the study. 
2.3. Test Products 
7.5 grams of commercially available VVR and petrolatum base (placebo) were 
packaged in identical individual 25 gram jars identifiable only by participant 
number. Participants were provided with 2 identical jars of either VVR or pla-
cebo at Day 0 with the instructions to apply all of the product from the first jar 
on the evening of Day 1 at bedtime, and all of the product from the second jar 
on the evening Day 2 at bedtime.  
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2.4. Sleep Measures 
The effect size of VVR on sleep was not expected to be large in absolute terms. 
Further, we were most interested in the subjective perceptions of sleep quality 
therefore change in the, “How was the quality of your sleep last night?” question 
of the SQSQ, a validated questionnaire which has been shown to be sensitive to 
effects of zolpidem, temazepam [25], gaboxadol and traffic noise [20] and slow 
wave sleep disruption by acoustic stimuli [26], was chosen as the primary end-
point. The KSD questionnaire [21], [27] was modified for this study by remov-
ing the first 5 questions due to duplication of sleep measures with the SQSQ. 
Actigraphy is considered a valid method to quantify sleep patterns in healthy 
controls, patients with sleep disorders and their treatment response [28]. This 
method was included in the study because if positive correlation with the subjec-
tive measures were observed, it would provide additional confidence in the effect 
and its magnitude. The Actiwatch 4® is a gyroscopic actigraphic device worn on 
the non-dominant wrist to collect objective indirect measurements of sleep and 
wakefulness (i.e., where movement is a surrogate for wakefulness) utilizing an 
automated computer and scoring algorithm. Derived sleep measures were total 
sleep time, sleep onset latency, mean activity score, percentage of sleep (per-
centage of actual sleep time between sleep onset and sleep end), sleep efficiency 
(percentage of time spent asleep from “Lights out” to “Lights on”), and number 
of sleep bouts. For computations of sleep and wakefulness the software algo-
rithm used the activity data recorded by the Actiwatch 4® in a series of linked 
calculations, such that each data point from each epoch and those surrounding 
was used to compute a total score based on these activity counts. With a default 
Medium Sensitivity, for 1-minute epoch data (and pro rata for other epochs 
used) a total score of 40 was designated as an “Awake” epoch. The activity scale 
was set to 2000. To determine “Sleep Start”, the algorithm looked for a period of 
at least 10 minutes of consecutively recorded immobile data, with no more than 
1 epoch of movement within that time, following the “Bed Time”. To determine 
‘Sleep End’, the algorithm looked for a 10-minute consecutive period of activity 
around the “Get Up Time” and then worked back to find the last epoch of im-
mobility. To set the analysis window, the actigraphy marker-based bedtime and 
get-up times were used. In instances, where subjects failed to use the markers, 
their sleep-diary based bedtime and get up times were used instead. 
2.5. Statistical Methods 
Randomization and Stratification of Participants: All potential study participants 
were given a subject number (starting at 1001 in the order in which they were 
screened for the study). Eligible volunteers were stratified by average LSEQ score 
on the 2 responses to the question “How would you compare the quality of last 
night’s sleep with your usual sleep without a cold?” (0 - 20.8 = “Very poor”; > 
20.8 - 35.4 = “Rather poor”; > 35.4 - < 50 = “Intermediate”). Participants were 
then randomly assigned to test products (VVR or placebo) using a block ran-
domization. A unique randomization number (e.g., 101, 102, 103, etc) was as-
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signed to each eligible participant. 
Safety Analyses: All safety summarization was done on Intent-to-Treat popu-
lation (all randomized subjects). 
Efficacy Analyses: All efficacy analyses were done on Per-Protocol population. 
The Per-Protocol population comprised those participants who were generally 
compliant with test product usage instructions (used ≥ half of the allocated dose) 
and met key inclusion and exclusion criteria. The Per-Protocol assessment was 
determined on blinded data prior to receiving treatment codes. In order to ob-
tain a more consistent response, the two treatment days (Day 1 and Day 2) for 
each endpoint were averaged for analysis purposes and served as the response 
variable for the analyses. 
Comparability of treatments at baseline for demographics, baseline character-
istics, SQSQ, post-sleep questionnaire, Actiwatch, and KSD was assessed via 2- 
sample t-test, Fisher’s exact test, and Cochran-Mantel-Haenszel test, as appro-
priate per the data type. Analysis of covariance (ANCOVA) was used for ana-
lyzing primary and secondary endpoints using the Mixed procedure of SAS ver-
sion 9.4 (SAS Institute, Cary, NC, USA).The primary endpoint was sleep quality 
as measured by the SQSQ. Each hypothesis was tested separately using an 
ANCOVA model that included relevant baseline measures as a covariate and 
treatment group as independent variable (fixed factor). The following hypothe-
ses were tested separately for each endpoint: 
Null Hypothesis: the change from baseline mean <insert endpoint> is the 
same for VVR versus placebo. Alternative Hypothesis: the change from baseline 
mean <insert endpoint> is different for VVR versus placebo. 
Two of the secondary KSD measures (“Did you take any drugs before retir-
ing?” and “Did you wake up ahead of time without being able to return to 
sleep?”) required nonparametric assessments as described in the protocol due to 
assumptions of ANCOVA not being met. All hypotheses were tested at a 
two-sided significance level of 5%. No corrections for multiplicity were con-
ducted in this exploratory investigation. 
2.6. Sample Size 
The sample size was determined by logistical considerations and previous ex-
perience with sleep studies.  
3. Results 
Demographics: Table 1 shows the demographic composition of the participants.  
Participant screening and baseline characteristics: common cold symptom se-
verity, PSQI, LSEQ (abbreviated, only displayed two Leeds questions that were 
part of inclusion criteria), SQSQ, KSD and Post-sleep questionnaire, did not dif-
fer between groups (Tables 1-3). 
Product Dosing Compliance: Product dosing compliance was assessed by 
weighing the sample jars before and after treatment. On average participants 
used 23% less product than instructed on both treatment nights. There were no  
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Table 1. Summary of demographics and baseline characteristics (Intent-to-treat). 
Parameter 
Statistic/Category 
VapoRub 
(N = 50) 
Petrolatum 
(N = 50) P value
1 
Age 23.1 (9.45) 23.7 (7.99) 0.7154 
Sex   0.6820 
Female 32 (64%) 29 (58%)  
Male 18 (36.0%) 21 (42%)  
Race   0.1287 
Caucasian 30 (60%) 41 (82%)  
Asian Indian 8 (16%) 1 (2%) 
 Black 3 (6%) 3 (6%) 
Other 9 (18%) 5 (10%) 
Height (cm) 170.5 (9.24) 170.9 (11.47) 0.8511 
Weight (kg) 69.5 (12.66) 67.7 (11.80) 0.4618 
BMI 23.8 (3.25) 23.1 (2.46) 0.1915 
Nasal Congestion   0.3696 
Mild 25 (50%) 23 (46%)  
Moderate 25 (50%) 24 (48%)  
Severe 0 (0%) 3 (6%)  
Cough   0.3235 
Mild 38 (76.0%) 33 (66%)  
Moderate 11 (22.0%) 16 (32%)  
Severe 1 (2%) 1 (2%)  
Runny Nose   0.7911 
Not Present 3 (6%) 1 (2%)  
Mild 16 (32%) 23 (46%)  
Moderate 25 (50%) 19 (38%)  
Severe 6 (12%) 7 (14%)  
Sore Throat   0.6862 
Not Present 8 (16%) 6 (12.0%)  
Mild 22 (44%) 24 (48.0%)  
Moderate 19 (38%) 18 (36.0%)  
Severe 1 (2%) 2 (4.0%)  
Sneezing   0.5225 
Not Present 13 (26%) 12 (24%)  
Mild 23 (46%) 22 (44%)  
Moderate 14 (28%) 14 (28%)  
Severe 0 (0%) 2 (4%)  
PSQI total2 2.8 (1.38) 2.9 (1.33) 0.8256 
Leeds Quality 1: More/Less Restful3 29.5 (15.68) 27.8 (12.35) 0.5646 
Leeds Quality 2: Fewer/More Periods Of Wakefulness4 34.2 (14.00) 32.9 (15.71) 0.6685 
Values are means (SD) or n(%) of subjects. 1P-values were calculated with 2 sample t-test for conti-
nuous variables, Fisher's exact test for non-ordered categorical variables, and Coch-
ran-Mantel-Haenszel test for ordered categorical variables. Continuous data that violated normality 
were also analyzed nonparametrically with the Wilcoxon Rank Sum Test with similar conclusions of 
no statistically significant difference (p > 0.05). 2Pittsburgh Sleep Quality Index. Leeds sleep evalua-
tion questionnaire question: “How would you compare the quality of last night’s sleep with your 
usual sleep without a cold?” 3A 100-mm Visual Analog Scale (VAS), where response is 0 = “Less 
restful than usual” and 100 = “More restful than usual”. 4A 100-mm Visual Analog Scale (VAS), 
where response is 0 = “More periods of wakefulness than usual” and 100 = “Fewer periods of wake-
fulness than usual”. 
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Table 2. Summary of subjective quality of sleep questionnaire, post-sleep questionnaire, 
and actiwatch for baseline (per-protocol). 
Parameter/Category VapoRub (N = 46) 
Petrolatum 
(N = 47) P value
1 
Subjective Quality of Sleep Questionnaire  
Wake Up Refreshed3 36.5 (15.59) 31.2 (20.00) 0.1575 
Sleep Quality2 60.8 (17.49) 65.1 (19.98) 0.2750 
Sleep Onset Latency (min) 25.1 (18.08) 26.4 (19.31) 0.7518 
Number of Awakenings 2.5 (2.11) 2.9 (2.03) 0.4154 
Total Sleep Time (min) 463.1 (57.76) 466.9 (46.96) 0.7337 
Wake After Sleep Onset (min) 19.1 (23.61) 18.8 (20.99) 0.9447 
Sleep Efficiency 89.5 (7.05) 89.7 (5.92) 0.8527 
Post-sleep Questionnaire  
How Easy Falling Asleep3 41.7 (17.01) 42.0 (23.85) 0.9472 
How Deep Was Sleep2 57.5 (19.15) 57.1 (23.14) 0.9291 
Actiwatch  
Total Sleep Time (min) 403.7 (65.97) 394.0 (40.77) 0.3939 
Sleep Onset Latency (min) 18.7 (28.70) 18.7 (25.47) 0.9992 
Mean Activity Score 21.9 (10.26) 21.3 (9.43) 0.7652 
Percentage of Sleep 83.4 (5.62) 83.1 (5.84) 0.8070 
Sleep Efficiency 79.9 (7.05) 79.2 (7.00) 0.6226 
Number of Sleep Bouts 32.9 (8.54) 32.1 (8.79) 0.6637 
Wake After Sleep Onset (min) 80.1 (28.14) 81.0 (32.64) 0.8829 
Values are means (SD). 1P-values were calculated with 2-sample t-test. Continuous data that violated nor-
mality were also analyzed nonparametrically with the Wilcoxon Rank Sum Test with similar conclusions of 
no statistically significant difference (p > 0.05). 2VAS with lower numbers better. 3VAS with higher num-
bers better. 
 
between-group differences—both groups used between 5.7 and 5.8 grams versus 
the supplied single-dose amount of 7.5 grams. The Per-Protocol analyses ex-
cluded seven participants for the nights they used less than half the allocated 
dose (3 VVR and 4 placebo participants).  
Table 4 shows the data from statistical testing of between group differences in 
the various subjective scales used. 
Subjective Quality of Sleep Questionnaire Endpoints: Statistical testing of the 
between group differences showed that the primary endpoint of Sleep Quality in 
the SQSQ showed a statistically significant difference in change from baseline in 
favour of VVR treatment compared to placebo (Table 4, Figure 2; p = 0.0392). 
This was also found for the “Wake up refreshed” SQSQ endpoint (Table 4, Fig-
ure 2; p = 0.0122). None of the other SQSQ endpoints showed statistically sig-
nificant between group differences (Table 4, Figure 2). Examination of the mo-
nadic changes from baseline were consistent with the between group findings: 
89% of participants who used VVR reported an improved quality of sleep vs  
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Table 3. Summary of Karolinska sleep diary for baseline (Per-Protocol). 
Parameter/Category VapoRub (N = 46) 
Petrolatum 
(N = 47) P value
1 
How well did you sleep   0.2227 
1-VERY POORLY 0 (0%) 4 (8.5%)  
2-RATHER POORLY 17 (37.0%) 20 (42.6%)  
3-INTERMEDIATE 23 (50.0%) 16 (34.0%)  
4-RATHER WELL 5 (10.9%) 6 (12.8%)  
5-VERY WELL 1 (2.2%) 1 (2.1%)  
Difficulties falling asleep   0.5029 
1-GREAT DIFFICULTIES 1 (2.2%) 4 (8.5%)  
2 13 (28.3%) 12 (25.5%)  
3-RATHER 13 (28.3%) 15 (31.9%)  
4 14 (30.4%) 10 (21.3%)  
5-NOT AT ALL 5 (10.9%) 6 (12.8%)  
Have a restless sleep   0.7131 
1-VERY 4 (8.7%) 6 (12.8%)  
2 14 (30.4%) 12 (25.5%)  
3-A LITTLE 15 (32.6%) 19 (40.4%)  
4 10 (21.7%) 6 (12.8%)  
5-NOT AT ALL 3 (6.5%) 4 (8.5%)  
How deep was your sleep   0.9959 
1-VERY LIGHT 3 (6.5%) 0 (0%)  
2-RATHER LIGHT 4 (8.7%) 15 (31.9%)  
3-INTERMEDIATE 28 (60.9%) 18 (38.3%)  
4-RATHER DEEP 10 (21.7%) 11 (23.4%)  
5-VERY DEEP 1 (2.2%) 3 (6.4%)  
How much did you dream   0.3483 
1-MUCH 0 (0%) 1 (2.1%)  
2 4 (8.7%) 5 (10.6%)  
3-A LITTLE 10 (21.7%) 10 (21.3%)  
4 4 (8.7%) 8 (17.0%)  
5-NOT AT ALL 28 (60.9%) 23 (48.9%)  
Did you get enough sleep   0.7085 
1-NO FAR TOO LITTLE 0 (0%) 0 (0%)  
2-NO TOO LITTLE 8 (17.4%) 11 (23.4%)  
3-NOT QUITE 16 (34.8%) 18 (38.3%)  
4-YES ALMOST 19 (41.3%) 11 (23.4%)  
5-YES DEFINITELY 3 (6.5%) 7 (14.9%)  
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Continued 
How was it to get up   0.4289 
1-VERY DIFFICULT 0 (0%) 4 (8.5%)  
2-RATHER DIFFICULT 20 (43.5%) 18 (38.3%)  
3-INTERMEDIATE 18 (39.1%) 17 (36.2%)  
4-RATHER EASY 6 (13.0%) 7 (14.9%)  
5-VERY EASY 2 (4.3%) 1 (2.1%)  
Do you feel well rested   0.3988 
1-NOT AT ALL 4 (8.7%) 7 (14.9%)  
2 20 (43.5%) 24 (51.1%)  
3-RATHER 16 (34.8%) 10 (21.3%)  
4 6 (13.0%) 4 (8.5%)  
5-FULLY 0 (0%) 2 (4.3%)  
What caused your final awakening   0.8701 
1-OTHER 3 (6.5%) 2 (4.3%)  
2-NEED BATHROOM 2 (4.3%) 1 (2.1%)  
3-NOISE 1 (2.2%) 2 (4.3%)  
4-ALARM CLOCK 30 (65.2%) 29 (61.7%)  
5-NOTHING PARTICULAR 10 (21.7%) 13 (27.7%)  
Take any drugs before retiring    
5-NO 46 (100%) 47 (100%)  
Occurrences that might have affected sleep   0.5698 
1-NO 36 (78.3%) 34 (72.3%)  
2-STRESS 2 (4.3%) 0 (0%)  
3-WORRIES 2 (4.3%) 3 (6.4%)  
4-DISEASE, PAIN 1 (2.2%) 2 (4.3%)  
5-HARD PHYSICAL WORK 2 (4.3%) 2 (4.3%)  
6-NOISE 3 (6.5%) 3 (6.4%)  
7-OTHER 0 (0%) 3 (6.4%)  
Wake up ahead of time not able to return to sleep   0.8571 
2 2 (4.3%) 2 (4.3%)  
3-SOMEWHAT EARLY 5 (10.9%) 7 (14.9%)  
4 5 (10.9%) 3 (6.4%)  
5-NO 34 (73.9%) 35 (74.5%)  
N = number of subjects within specified treatment. n(%) = number and percentage of subjects within speci-
fied parameter, treatment, and category. 1P-values were calculated with Fisher’s exact test and Coch-
ran-Mantel-Haenszel test, as appropriate per the data type. 
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Table 4. Analysis of covariance of subjective sleep questionnaires and diaries (Per-Protocol). 
 Change From Baseline 
Endpoint 
Count Adjusted Mean (SE) Adjusted Mean (SE) Treatment Difference 
VapoRub Petrolatum VapoRub Petrolatum VapoRub Petrolatum Adjusted Mean (SE) P-value 
Subjective Quality of Sleep Questionnaire 
Sleep Quality1 46 47 41.4 (2.68) 49.3 (2.65) −21.6 (2.68) −13.7 (2.65) −7.9 (3.78) 0.0392 
Wake Up Refreshed2 46 47 53.5 (2.33) 45.0 (2.30) 19.6 (2.33) 11.2 (2.30) 8.4 (3.29) 0.0122 
Sleep Onset Latency (min) 46 47 21.8 (2.22) 22.6 (2.20) −4.0 (2.22) −3.2 (2.20) −0.8 (3.13) 0.7929 
Number of Awakenings 46 47 1.3 (0.17) 1.7 (0.17) −1.3 (0.17) −1.0 (0.17) −0.3 (0.25) 0.2048 
Total Sleep Time (min) 46 47 471.2 (5.91) 472.3 (5.84) 6.2 (5.91) 7.3 (5.84) −1.1 (8.31) 0.8988 
Wake After Sleep Onset (min) 46 47 10.0 (1.49) 12.1 (1.48) −9.0 (1.49) −6.9 (1.48) −2.1 (2.10) 0.3271 
Sleep Efficiency 46 47 92.3 (0.77) 91.7 (0.76) 2.7 (0.77) 2.1 (0.76) 0.6 (1.08) 0.5505 
Karolinska Sleep Diary         
How well did you sleep 46 47 3.5 (0.11) 3.3 (0.11) 0.9 (0.11) 0.7 (0.11) 0.2 (0.16) 0.2272 
Difficulties falling asleep 46 47 3.6 (0.12) 3.4 (0.12) 0.5 (0.12) 0.3 (0.12) 0.2 (0.17) 0.2732 
Have a restless sleep 46 47 3.6 (0.12) 3.4 (0.12) 0.8 (0.12) 0.6 (0.12) 0.2 (0.17) 0.2843 
How deep was your sleep 46 47 3.7 (0.09) 3.5 (0.09) 0.6 (0.09) 0.5 (0.09) 0.1 (0.13) 0.3444 
How much did you dream 46 47 3.9 (0.13) 3.8 (0.13) −0.2 (0.13) −0.3 (0.13) 0.1 (0.18) 0.6127 
Did you get enough sleep 46 47 3.9 (0.11) 3.4 (0.11) 0.6 (0.11) 0.1 (0.11) 0.5 (0.16) 0.0036 
How was it to get up 46 47 3.5 (0.11) 3.1 (0.11) 0.8 (0.11) 0.4 (0.11) 0.4 (0.15) 0.0120 
Do you feel well rested 46 47 3.4 (0.11) 3.0 (0.11) 0.9 (0.11) 0.5 (0.11) 0.4 (0.16) 0.0125 
  What caused your final awakening 46 47 4.1 (0.10) 4.1 (0.09) 0.1 (0.10) 0.1 (0.09) 0.0 (0.13) 0.8840 
Occurrences that might  
have affected Sleep 46 47 1.7 (0.19) 2.0 (0.19) −0.2 (0.19) 0.0 (0.19) −0.2 (0.26) 0.4165 
Sleep Quality Index 46 47 3.9 (0.08) 3.7 (0.08) 0.6 (0.08) 0.5 (0.08) 0.1 (0.11) 0.3124 
Post−sleep Questionnaire 
How Easy Falling Asleep2 45 46 52.1 (2.59) 50.5 (2.56) 10.3 (2.59) 8.6 (2.56) 1.6 (3.64) 0.6564 
How Deep Was Sleep1 46 47 38.1 (2.21) 44.0 (2.18) −19.2 (2.21) −13.3 (2.18) −5.9 (3.11) 0.0606 
1. 0 - 100 VAS scale where lower values are better (negative treatment difference better); 2. 0 - 100 VAS scale where higher values are better (positive treat-
ment difference better). 
 
baseline, and 91% who used VVR reported an improved “wake up refreshed” 
score vs baseline. In examining the consistency of response of the primary end-
point (sleep quality as measured by SQSQ), subgroup analyses by demographics 
and baseline characteristics were assessed. The results for all subgroups analysed 
favoured VVR compared to placebo, indicating consistency of response. Statis-
tical significance of VVR vs. placebo for sleep quality was observed in the sub-
group of subjects with moderate-to severe cough at baseline (p = 0.0294), runny 
nose not present/mild at baseline (p = 0.0492) and PSQI ≥ 3 (p = 0.0486) (Data 
not shown). 
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(a) 
 
(b) 
Figure 2. (a) Plot of mean differences and 95% Confidence Intervals for each of the Sub-
jective Quality of Sleep Questionnaire (SQSQ) questions comparing answers provided 
“on awakening” with baseline; (b) Primary. Histogram showing the statistical analysis of 
results from the SQSQ question identified a piori as Primary Objective comparing an-
swers provided “on awakening” with baseline. Visual Analogue Scale–“How was the qual-
ity of your sleep last night?” 0 = “Very Good” and 100 = “Very Bad”. Between group dif-
ference statistically significant at p < 0.0392. (b) Secondary. Histogram showing the sta-
tistical analysis of results from the SQSQ question identified a piori as “First Secondary 
Objective”, comparing answers provided “on awakening” with baseline. Visual Analogue 
Scale–“How refreshed did you feel upon waking up?” 0 = “Very Good” and 100 = “Very 
Bad”. Between group difference statistically significant at p < 0.0122. 
 
Karolinska Sleep Diary Endpoints: Statistical testing of the KSD endpoints 
showed significant between group differences for “Did you get enough sleep?” (p 
= 0.0036), “How was it to get up?” (p = 0.0120) and “Do you feel well-rested?” (p 
= 0.0125) favouring VVR compared to placebo (Table 4, Figure 3). While none 
of the other KSD or Post-sleep Questionnaire endpoints reached statistical sig-
nificance, VVR treatment showed a numerical improvement in the KSD results 
(Table 4 & Figure 3). The two secondary KSD measures (“Did you take any  
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Figure 3. Plot of mean differences and 95% Confidence Intervals for each of the Karo-
linska Sleep Diary (KSD) questions comparing answers provided “on awakening” with 
baseline.  
 
drugs before retiring?” and “Did you wake up ahead of time without being able 
to return to sleep?”) analyzed by nonparametric measures did not show signifi-
cant treatment differences (data not shown). A trend in favour of VVR com-
pared to placebo (p = 0.0606), was observed in change from baseline for the 
“How deep was sleep?” endpoint in the Post-sleep Questionnaire but no differ-
ence in ease of falling asleep (Table 4).  
Actigraphy Endpoints: There were no statistically significant changes from 
baseline treatment differences in the Actiwatch endpoints. There was, however, a 
trend in favour of VVR compared to placebo for change from baseline in Sleep 
Onset Latency (Table 5, Figure 4; treatment difference 11.5 minutes and p = 
0.0538).  
Safety 
Both treatments were well-tolerated during this study. There were no deaths, se-
rious or other significant Adverse Events (AEs). Eight participants reported 10 
AEs; 5 on placebo and 3 on VVR and all resolved without any action being taken 
to ameliorate the AE.  
4. Discussion 
The results from this exploratory study show for the first time that application of 
Vicks VapoRub® before retiring to bed has a positive effect on perceived sleep 
quality for adults suffering from symptoms of common cold. The primary end-
point subjective finding supports the long-held association described by com-
mon cold patients of VVR use and improved sleep. It cannot be determined 
from these data alone whether this is a result of symptom relief facilitating sleep 
(as has been suggested for cough relief [29]) or a direct effect on sleep. However, 
the active ingredients in VVR are not known to have a sedative effect. This sug-
gests that a patient-perceived sleep quality benefit in patients with a cold would 
be due to a different mechanism, likely symptom relief. Indeed, the subgroup of 
patients with moderate-to-severe cough at baseline reported improvement for 
sleep quality vs placebo (p = 0.0294).  
N. Santhi et al. 
 
97 
Table 5. Analysis of covariance of Actiwatch (Per-Protocol). 
 Change From Baseline 
Endpoint 
Count Adjusted Mean (SE) Adjusted Mean (SE) Treatment Difference 
VapoRub Petrolatum VapoRub Petrolatum VapoRub Petrolatum Adjusted Mean (SE) P-value 
Total Sleep Time (min) 46 47 394.9 (7.44) 381.8 (7.36) −3.9 (7.44) −17.1 (7.36) 13.2 (10.48) 0.2124 
Sleep Onset Latency (min) 46 47 18.8 (4.18) 30.3 (4.14) 0.1 (4.18) 11.6 (4.14) −11.5 (5.88) 0.0538 
Mean Activity Score 46 47 21.4 (1.49) 23.7 (1.48) −0.2 (1.49) 2.1 (1.48) −2.3 (2.10) 0.2820 
Percentage of Sleep 46 47 83.6 (0.78) 82.7 (0.77) 0.4 (0.78) −0.6 (0.77) 1.0 (1.10) 0.3837 
Sleep Efficiency 46 47 79.6 (1.16) 76.9 (1.15) 0.0 (1.16) −2.6 (1.15) 2.7 (1.64) 0.1050 
Number of Sleep Bouts 46 47 30.1 (0.91) 29.8 (0.90) −2.3 (0.91) −2.7 (0.90) 0.3 (1.28) 0.8077 
Wake After Sleep Onset (min) 46 47 76.5 (3.82) 80.1 (3.78) −4.0 (3.82) −0.5 (3.78) −3.5 (5.38) 0.5122 
 
 
Figure 4. Plot of mean differences and 95% Confidence Intervals for each of the Acti-
watch endpoints comparing answers provided on awakening with those at baseline. 
 
It was hypothesised that VVR would affect sleep as a result of its known de-
congestion and antitussive effects rather than as a sleep aid. Consequently, while 
for completeness both subjective and objective assessments of sleep were em-
ployed, it was predicted that subjective endpoints were most likely to be affected. 
Change in the SQSQ sleep quality was chosen as the primary objective as it of-
fered a global retrospective assessment of the perceived sleep experience. The 
KSD was also included as a source of secondary endpoints to permit a more 
granular description of the subjective elements of sleep affected. As nasal de-
congestion and cough relief are the licensed indications of VVR in the UK, they 
were not measured in this study wherein the focus was sleep-related effects. 
The difference in perceived sleep quality assessed by the SQSQ was statistically 
significant (p = 0.0392). To place this change in perspective it is noted that the 
observed response to VVR compared to placebo for the SQSQ was 7.9 units, 
which is comparable to the positive effects of gaboxadol on subjective sleep qual-
ity in a traffic noise model of sleep disruption [20] and approximately half the 
size of the effect of zolpidem and temazapam on sleep in middle-aged people 
[25]. Supporting this is the finding that responses to the “How refreshed did you 
feel upon waking?” SQSQ endpoint were also significant (p = 0.0122). On aver-
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age subjects had 58% better sleep quality vs. placebo and 75% better wake up re-
freshed vs. placebo. The effect sizes for questions [30] would be considered a 
moderate effect (0.44 and 0.54 respectively). Taken together these findings sug-
gest that VVR had a clinically relevant effect on the perception of sleep quality. 
We speculate that as subjective sleep assessments are necessarily retrospective, 
the fact that the VVR aroma would still be noticeable in the morning may have 
augmented the perception of improved sleep quality.  
The SQSQ also includes a series of more specific time and duration related 
questions. Changes in these parameters did not reach statistical significance, 
consistent with the objective actigraphy results except for sleep onset latency 
which objectively favoured VVR with subjects falling asleep approximately 11.5 
minutes faster than placebo (p = 0.0538). Arguably, questions around for exam-
ple, time to get to sleep, number of awakenings, duration of awakenings, etc. re-
quire an awareness of sleep and sleep disruption that may be difficult to measure 
in patients with an illness such as the common cold relative to other conditions; 
further studies would be useful. It seems reasonable to expect greater effects if 
subjects had more severe symptoms and/or more severe sleep disturbance at 
baseline.  
There were also positive findings for some of the secondary endpoints as-
sessed by the KSD. Participants provided positive (for VVR) between group re-
sponses for, “Did you get enough sleep?” (p = 0.0036), “How was it to get up?” 
(p = 0.0120) and “Do you feel well-rested?” (p = 0.0125). The effect size for the 
significant KSD questions (0.62, 0.53, and 0.53 respectively) would be considered 
moderate effects [30]. These parameters may be considered to be elements of the 
overall findings of improved sleep quality and the feelings of having had re-
freshing sleep. They are consistent with improvements in an improved overall 
sleep experience. The remaining KSD parameters including, “How did you 
sleep?” and sleep quality index, did not show a statistical significant effect.  
The objective effects on sleep were assessed using arm motion during rest as a 
surrogate measure for wakefulness. The Actiwatch instrument has been vali-
dated for the assessment of a variety of sleep parameters [28] [31]. We believe 
this study is the first use of actigraphy in the investigation of the mild sleep dis-
turbance associated with common cold. The Actiwatch and subjective data were 
broadly consistent. In this study of sleep disturbance associated with common 
cold, no significant between-group differences were detected in the objective da-
ta-only “Sleep Onset Latency” approached statistical significance (p = 0.0538). 
Several limitations of this study merit discussion. An obvious limitation is that 
it was not double-blind. As the Informed Consent information made clear that 
participants would be treated either with an aromatic or non-aromatic product, 
those allocated VVR would have been aware that they had received active prod-
uct as soon as they sensed the aroma. The difficulty in designing double-blind 
studies with VVR is a recognized design limitation [32]. It is difficult to blind a 
study wherein the aroma of the product is so widely recognized and represents 
the pharmacological effect. Investigators were blinded as no medication was 
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opened at the study site thus preserving the single blind. 
Finally, while these data indicate a positive effect of VVR on sleep quality they 
cannot distinguish between VVR treatment improving sleep quality solely as a 
result of reducing the symptoms, exerting a direct sleep effect or a combination 
of both. Further work is recommended wherein the direct sleep quality benefit in 
persons with sleep disturbance and no infectious disease is examined. 
5. Conclusion 
Common cold sufferers using Vicks VapoRub® (applied before retiring to bed) 
experienced significant differences in self-reported sleep quality compared to 
control. This supports that treatment with this product can be a valuable com-
ponent in the armamentarium of safe and effective common cold therapies due 
to the patient perceived improvement in sleep quality, a widespread patient be-
lief measured in this study. 
Financial and Competing Interests 
This work was sponsored in full by Procter & Gamble. At the time of conducting 
the study and preparing this manuscript, DH, GP and DR were full-time em-
ployees of The Procter & Gamble Company and may have stock and/or stock 
options in the company. VR, NS and DJD did not receive any financial payments 
or other inducement apart from their usual university salary, for conducting this 
study. 
DH and DR were responsible for statistical analysis (DR) interpretation of 
study results (DH, DR) and publication drafting (DH). VR, NS and DJD were 
responsible for study execution. GP advised on design and was responsible for 
product supply and management. All attributed authors participated in the de-
velopment and review of this manuscript. 
Acknowledgements 
The authors gratefully acknowledge the assistance of J. Brum, G. Kappler and P. 
Thomas of Procter & Gamble in study design and for excellence in protocol de-
velopment and study management. Also acknowledged is the expert advice of 
Ian Barton (Procter & Gamble) during study design. 
Thanks also to the Clinical Research and Medical teams at the Surrey Clinical 
Research Centre. 
References 
[1] Wat, D. (2004) The Common Cold: A Review of the Literature. European Journal of 
Internal Medicine, 15, 79-88. 
[2] Heikkinen, T. and Järvinen, A. (2003) The Common Cold. The Lancet, 361, 51-59. 
[3] Eccles, R. (2013) Is the Common Cold a Clinical Entity or a Cultural Concept? 
Rhinology, 51, 3-8. 
[4] Eccles, R. (2005) Understanding the Symptoms of the Common Cold and Influenza. 
The Lancet Infectious Diseases, 5, 718-725. 
N. Santhi et al. 
 
100 
[5] Witek, T.J., et al. (2015) The Natural History of Community-Acquired Common 
Colds Symptoms Assessed over 4-Years. Rhinology, 53, 81-88.  
https://doi.org/10.4193/Rhin14.149 
[6] Smith, A.P. (2012) Sleep and the Common Cold. Journal of Behavioral Health, 1, 
114-117. https://doi.org/10.5455/jbh.20120322073850 
[7] Drake, C.L., et al. (2000) Effects of an Experimentally Induced Rhinovirus Cold on 
Sleep, Performance, and Daytime Alertness. Physiology & Behavior, 71, 75-81. 
[8] Packman, E.W. and London, S.J. (1980) The Utility of Artificially Induced Cough as 
a Clinical Model for Evaluating the Antitussive Effects of Aromatics Delivered by 
Inunction. European Journal of Respiratory Diseases, 110, 101-109. 
[9] Eccles, R., et al. (2015) Efficacy of a Topical Aromatic Rub (Vicks VapoRub®)-Speed 
of Action of Subjective Nasal Cooling and Relief from Nasal Congestion. Open 
Journal of Respiratory Diseases, 5, 10-18. https://doi.org/10.4236/ojrd.2015.51002 
[10] Meltzer, E.O. (2002) Does Rhinitis Compromise Night-Time Sleep and Daytime 
Productivity? Clinical & Experimental Allergy Reviews, 2, 67-72.  
https://doi.org/10.1046/j.1472-9725.2002.00039.x 
[11] Dicpinigaitis, P.V., et al. (2009) Acute Cough: A Diagnostic and Therapeutic Chal-
lenge. Cough, 16, 11. https://doi.org/10.1186/1745-9974-5-11 
[12] Sabharwal, G. and Craig, T.J. (2016) The Effect of Rhinitis on Sleep, Quality of Life, 
Daytime Somnolence, and Fatigue. In: Mahmoudi, M., Ed., Allergy and Asthma, 
Springer International Publishing, Berlin, 87-97.  
https://doi.org/10.1007/978-3-319-30835-7_7 
[13] Omar, S., et al. (2017) Respiratory Virus Infection Up-Regulates TRPV1, TRPA1 
and ASICS3 Receptors on Airway Cells. PLoS ONE, 12, e0171681. 
[14] Abdullah, H., et al. (2014) Rhinovirus Upregulates Transient Receptor Potential 
Channels in a Human Neuronal Cell Line: Implications for Respiratory Vi-
rus-Induced Cough Reflex Sensitivity. Thorax, 69, 46-54.  
https://doi.org/10.1136/thoraxjnl-2013-203894 
[15] McKemy, D.D., et al. (2002) Identification of a Cold Receptor Reveals a General 
Role for TRP Channels in Thermosensation. Nature, 416, 52-58.  
https://doi.org/10.1038/nature719 
[16] Bautista, D.M., et al. (2007) The Menthol Receptor TRPM8 Is the Principal Detector 
of Environmental Cold. Nature, 448, 204-208. https://doi.org/10.1038/nature05910 
[17] Xu, H., et al. (2005) Camphor Activates and Strongly Desensitizes the Transient 
Receptor Potential Vanilloid Subtype 1 Channel in a Vanilloid-Independent 
Mechanism. Journal of Neuroscience, 25, 8924-8937.  
https://doi.org/10.1523/JNEUROSCI.2574-05.2005 
[18] Juergens, U.R. (2014) Anti-Inflammatory Properties of the Monoterpene 
1.8-Cineole: Current Evidence for Co-Medication in Inflammatory Airway Dis-
eases. Drug Research, 64, 638-646. https://doi.org/10.1055/s-0034-1372609 
[19] Caceres, A.I., et al. (2017) Transient Receptor Potential Cation Channel Subfamily 
M Member 8 Channels Mediate the Anti-Inflammatory Effects of Eucalyptol. Brit-
ish Journal of Pharmacology, 174, 867-879. https://doi.org/10.1111/bph.13760 
[20] Dijk, D.-J., et al. (2012) Enhanced Slow Wave Sleep and Improved Sleep Mainten-
ance after Gaboxadol Administration during Seven Nights of Exposure to a Traffic 
Noise Model of Transient Insomnia. Journal of Psychopharmacology, 26, 1096- 
1107. https://doi.org/10.1177/0269881111421971 
[21] Akerstedt, T., et al. (1994) The Subjective Meaning of Good Sleep, an In-
tra-Individual Approach Using the Karolinska Sleep Diary. Perceptual and Motor 
N. Santhi et al. 
 
101 
Skills, 79, 287-296. https://doi.org/10.2466/pms.1994.79.1.287 
[22] Sadeh, A. (2011) The Role and Validity of Actigraphy in Sleep Medicine: An Up-
date. Sleep Medicine Reviews, 15, 259-267. 
[23] Parrott, A.C. and Hindmarch, I. (1980) The Leeds Sleep Evaluation Questionnaire 
in Psychopharmacological Investigations—A Review. Psychopharmacology, 71, 
173-179. https://doi.org/10.1007/BF00434408 
[24] Buysse, D.J., et al. (1989) The Pittsburgh Sleep Quality Index: A New Instrument for 
Psychiatric Practice and Research. Psychiatry Research, 28, 193-213. 
[25] Arbon, E.L., et al. (2015) Randomised Clinical Trial of the Effects of Pro-
longed-Release Melatonin, Temazepam and Zolpidem on Slow-Wave Activity dur-
ing Sleep in Healthy People. Journal of Psychopharmacology, 29, 764-776.  
https://doi.org/10.1177/0269881115581963 
[26] Dijk, D.J., et al. (2010) Age-Related Reduction in Daytime Sleep Propensity and 
Nocturnal Slow Wave Sleep. Sleep, 33, 211-223.  
https://doi.org/10.1093/sleep/33.2.211 
[27] Åkerstedt, T., et al. (1994) The Meaning of Good Sleep: A Longitudinal Study of 
Polysomnography and Subjective Sleep Quality. Journal of Sleep Research, 3, 152- 
158. https://doi.org/10.1111/j.1365-2869.1994.tb00122.x 
[28] Morgenthaler, T., et al. (2007) Practice Parameters for the Use of Actigraphy in the 
Assessment of Sleep and Sleep Disorders: An Update for 2007. Sleep, 30, 519-529.  
https://doi.org/10.1093/sleep/30.4.519 
[29] Cohen, H.A., et al. (2012) Effect of Honey on Nocturnal Cough and Sleep Quality: 
A Double-Blind, Randomized, Placebo-Controlled Study. Pediatrics, 130, 465-471.  
https://doi.org/10.1542/peds.2011-3075 
[30] Cochrane Organisation (2017).  
http://handbook.cochrane.org/chapter_12/12_6_2_re_expressing_smds_using_rules
_of_thumb_for_effect_sizes.htm  
[31] Ancoli-Israel, S., et al. (2003) The Role of Actigraphy in the Study of Sleep and Cir-
cadian Rhythms. Sleep, 26, 342-392. https://doi.org/10.1093/sleep/26.3.342 
[32] Paul, I.M., et al. (2010) Vapor Rub, Petrolatum, and No Treatment for Children 
with Nocturnal Cough and Cold Symptoms. Pediatrics, 126, 1092-1099.  
https://doi.org/10.1542/peds.2010-1601 
 
 
 
 
 
Submit or recommend next manuscript to SCIRP and we will provide best 
service for you:  
Accepting pre-submission inquiries through Email, Facebook, LinkedIn, Twitter, etc.  
A wide selection of journals (inclusive of 9 subjects, more than 200 journals) 
Providing 24-hour high-quality service 
User-friendly online submission system  
Fair and swift peer-review system  
Efficient typesetting and proofreading procedure 
Display of the result of downloads and visits, as well as the number of cited articles   
Maximum dissemination of your research work 
Submit your manuscript at: http://papersubmission.scirp.org/ 
Or contact ojrd@scirp.org   
